Articles Vol. 67 No. CĐ6-NCKH 16/06/2026

A SURVEY ON THE RATE OF OSTEOPOROSIS TREATMENT AFTER PERCUTANEOUS VERTEBROPLASTY WITH BIOLOGIC CEMENT IN PATIENTS WITH THORACOLUMBAR VERTEBRAL COMPRESSION FRACTURES DUE TO OSTEOPOROSIS

Tran Van Sang1,2,3,4, Tran Minh Huy2,4, Nguyen Ngoc Khang5,6
1 Da Nang C Hospital
2 Ho Chi Minh City University of Medicine and Pharmacy
3 Bệnh viện C Đà Nẵng
4 Đại học Y dược Thành phố Hồ Chí Minh
5 Gia An 115 Hospital
6 Bệnh viện Gia An 115
DOI: 10.52163/yhc.v67iCD6.5318
23 Views
0 Downloads
Abstract

Introduction: Osteoporotic vertebral compression fractures cause prolonged back pain, reduced mobility, and a lower quality of life. Percutaneous vertebroplasty provides rapid pain relief, but the rate of post-operative osteoporosis treatment is inconsistent, which increases the risk of refracture.

Objective: To survey the rate of osteoporosis treatment and identify factors associated it after percutaneous vertebroplasty in patients with thoracolumbar vertebral compression fractures due to osteoporosis.

Methods: A cross-sectional descriptive study was conducted on 38 patients treated at the Department of Neurosurgery, Cho Ray Hospital from January 2024 to March 2025.

Results and Discussion: Following percutaneous vertebroplasty, 100% of patients were prescribed Calcium and Vitamin D supplements. Although essential for general bone health, Calcium and Vitamin D have limited and inconsistent effects on reducing the risk of vertebral fractures in the elderly. Therefore, specialized anti-osteoporotic therapy is required. Our study found that 86.8% of patients received specialized treatment, including: oral Bisphosphonates 63.2% of patients, intravenous Bisphosphonates 21.1%, and Calcitonin 18.4%. Five patients did not receive anti-resorptive, bone-forming and dual-action medications for the following reasons: lack of counseling, financial constraints, and the cessation of pain after surgery.

Conclusion: It is necessary to improve patient counseling regarding osteoporosis treatment to help them understand its importance. Additionally, collaboration between the Department of Musculoskeletal Internal Medicine and the Department of Neurosurgery is needed to enhance treatment effectiveness.

References
[1]
Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Archives of osteoporosis. 2017;12:1-24. https://doi.org/10.1007/s11657-017-0324-5 Google Scholar
[2]
Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. New England Journal of Medicine. 2006;354(7):669-683. DOI: 10.1056/NEJMoa055218 Google Scholar
[3]
Kanis JA, Harvey NC, Johansson H, et al. FRAX update. Journal of Clinical Densitometry. 2017;20(3):360-367. https://doi.org/10.1016/j.jocd.2017.06.022 Google Scholar
[4]
Bộ Y tế. Quyết định 361/QĐ-BYT ngày 25/1/2014 về việc “Ban hành về Hướng dẫn chẩn đoán và điều trị bệnh lý xương khớp”. 2014:169-171. Google Scholar
[5]
Ferrari S, Lippuner K, Lamy O, Meier C. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss medical weekly. 2020;150(3940):w20352-w20352. DOI: 10.4414/smw.2020.20352 Google Scholar
[6]
Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Archives of osteoporosis. 2022;17(1):58. https://doi.org/10.1007/s11657-022-01061-5 Google Scholar
[7]
Mehta N, Malootian A, Gilligan J. Calcitonin for osteoporosis and bone pain. Current pharmaceutical design. 2003;9(32):2659-2676. https://doi.org/10.2174/1381612033453622 Google Scholar
[8]
Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. The American journal of medicine. 2000;109(4):267-276. https://doi.org/10.1016/S0002-9343(00)00490-3 Google Scholar